57f33dc4_id_reviews__first_test_results__Cochrane_conclusion
[Our score] 0.22 [Our narrative conclusion] unclear benefit [Agree?] N [Cochrane conclusion] 
Meta-analysis demonstrates that topiramate in a 100 mg/day dosage is effective in reducing headache frequency and reasonably well-tolerated in adult patients with episodic migraine. This provides good evidence to support its use in routine clinical management. More studies designed specifically to compare the efficacy or safety of topiramate versus other interventions with proven efficacy in the prophylaxis of migraine are needed.
Liberating the literature: Ultra-rapid reviews, first test results
Cochrane conclusion